Unknown PHASE1 INTERVENTIONAL 1-arm NCT00881816

Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

Phase I Clinical Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

Sponsor: Nanjing Sike Pharmaceutical Co., Ltd.

Interventions Liposomal paclitaxel plus capecitabine

Updated 4 times since 2017 Last updated: Apr 14, 2009 Started: Apr 30, 2009 Primary completion: Oct 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00881816, this PHASE1 trial focuses on Advanced Gastric Carcinoma and remains ongoing. Sponsored by Nanjing Sike Pharmaceutical Co., Ltd., it has been updated 4 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE1

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanjing Sike Pharmaceutical Co., Ltd.

Data source: Nanjing Sike Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.